期刊文献+

Bcl-2在ER+和ER-乳腺癌中的表达差异及意义

The Different Expression and Significance of the Bcl-2 in the ER+ and ER- Breast Cancer
下载PDF
导出
摘要 目的:探讨Bcl-2在ER+和ER-乳腺癌中的表达差异及意义。方法:采用SP法检测Bcl-2在36例ER+(组织学Ⅰ级5例,Ⅱ级20例,Ⅲ级11例;伴同侧腋窝淋巴结转移13例,不伴同侧腋窝淋巴结转移23例)和31例ER-乳腺癌(组织学分级Ⅰ级4例,Ⅱ级21例,Ⅲ级6例;伴同侧腋窝淋巴结转移12例,不伴同侧腋窝淋巴结转移19例)中的表达,用其周围正常组织(手术缺损区组织)作对照,分析其在ER+和ER-乳腺癌中的表达差异及其与乳腺癌发生发展及治疗、预后的关系。结果:Bcl-2在乳腺癌和癌旁组织中阳性表达率分别为61.19%(41/67)和22.39%(15/67),其表达差异具有统计学意义(P<0.05)。Bcl-2在ER+和ER-乳腺癌中的阳性表达率分别为77.78%(28/36)、41.94%(13/31),其在ER+乳腺癌中的表达明显高于在ER-乳腺癌中的表达,差异具有统计学意义(P<0.05)。Bcl-2在ER+乳腺癌组织学分级Ⅰ、Ⅱ、Ⅲ级中的表达率分别为80%(4/5)、75%(15/20)、72.73%(8/11),其阳性表达率差异无统计学意义(P>0.05)。Bcl-2在ER+乳腺癌伴同侧腋窝淋巴结转移和ER+乳腺癌不伴同侧腋窝淋巴结转移的阳性表达率分别为76.92%(10/13)、78.26%(18/23),其阳性表达率差异无统计学意义(P>0.05)。结论:Bcl-2与乳腺癌的发生关系密切,且其表达与ER+表达关系密切。 Objective:To explore the different expression and significance of the Bcl-2 in the ER+ and ER- breast cancer.Methods:Using SP method to detect the expression of Bcl-2 in 36 patients with ER+(histological gradeⅠin 5 cases,20 cases of classⅡ,Ⅲgrade 11 cases,accompany side axillary lymph node metastases 13 cases,not accompany side axillary lymph node metastasis 23 cases)and 31 cases of ER-breast cancer (histological grade four cases classⅠand classⅡ21 cases,6 cases of levelⅢ,12 cases accompany side axillary lymph node metastasis,not accompany side axillary lymph node metastasis in 19),and with its surrounding normal tissues(surgical defect tissue)as control to analyze its expression differences in ER+ and ER- breast cancer and its relationship with the occurrence and development, treatment and prognosis of breast cancer.Results:The expression of Bcl-2 in breast cancer and cancer adjacent tissues was 61.19%(41/67) and 22.39%(15/67),and its expression differences statistically significant(P〈0.05).The expression of Bcl-2 in the positive expression rate of ER+and ER-breast cancer was 77.78%(28/36),41.94%(13/31),its expression was significantly higher in the ER+breast cancer in the ER- expression in breast cancer,statistically significant difference(P〈0.05).The expression of Bcl-2 in the ER+breast cancer in the histologic classificationⅠ,Ⅱ,Ⅲclass expression rate was 80%(4/5)and 75%(15/20),72.73%(8/11),the positive expression rate difference has no statistical significance(P〉0.05).The expression of Bcl-2 in the ER+ breast cancer accompany side axillary lymph node metastasis and not accompany side were 76.92%(10/13),78.26%(18/23),there was no statistically significant difference(P〉0.05).Conclusion:The expression of Bcl-2 closely associated with the occurrence of breast cancer,indicate its have important value in diagnosis of breast cancer,and its expression of ER+ close relationship,indicates its treatment and prognosis of breast cancer has important value in the j udgment.
出处 《长治医学院学报》 2014年第3期175-177,共3页 Journal of Changzhi Medical College
关键词 乳腺癌 BCL-2 免疫组化 ER ER Breast cancer Bel-2 Immunohistochemistry ER
  • 相关文献

参考文献9

  • 1Lvkovic-Kapicl T, Knezevic-Usaj S, Panjkovie M, et al. The influence of aging on pathologic and immunobiologic parameters of invasive ductal breast carcinoma[J]. Vojnosanit Pregl, 2006,63 (11) : 921-927.
  • 2Kim R, Emi M, Matsuura K, et al. Therapeutic potential of antisense(AS):Bcl-2 as a chemosensitizer for patients with gastric and breast carcinoma[J]. Gan To Kagaku Ryoho, 2005, 32 ( 11 ) : 1540-1545.
  • 3Chami M, Prandini A, Campanella M, et al. Bcl-2 and Bax exert opposing effect On Ca^2+ signaling, which do not depend on their putative pore-forming region[J]. Biol Chem, 2004,279 (52) : 545-581.
  • 4黑静雅,黄凌燕,张建中.caspase3、bcl-2蛋白在乳腺癌中表达的临床病理研究[J].宁夏医学杂志,2010,32(1):17-19. 被引量:14
  • 5Schymik B,Buerger H,Kramer A, et al. Is there' progression through grade' in duetal invasive breast cancer[J]. Breast Cancer Res Treat, 2012,135 (3) : 693-703.
  • 6Milella, Trisciuoglio D, Bruno T, et al. Down-regulates bel-2 expression and potentiates apoptosis induction by bcl-2/bcl-XL bispeeifle antisense oligonueleotides in HER-2 gene-amplified breast cancer cells[J]. Clinical Cancer Research,2004,10(7):7747-7756.
  • 7Rolland P,Spendlove I,Madjd Z,et al. The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer[J].Int J Caneer,2007,120(6):1311-1137.
  • 8Lee K H,Im S A,Oh D Y, et al. Prognostic significance of Bcl-2 expression in stage II breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy[J]. BMC Cancer, 2007,7 :63-71.
  • 9Kyndi M,Sorensen F B,Knudsen H, et al. Impact of Bcl-2 and p53 on postmastectomy radiotherapy response in high-risk breast cancer. A subgroupanalysis of DBCG82b&c[J]. Acta Oncol, 2008,47 (4) :608-617.

二级参考文献11

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部